<code id='50E87A28D9'></code><style id='50E87A28D9'></style>
    • <acronym id='50E87A28D9'></acronym>
      <center id='50E87A28D9'><center id='50E87A28D9'><tfoot id='50E87A28D9'></tfoot></center><abbr id='50E87A28D9'><dir id='50E87A28D9'><tfoot id='50E87A28D9'></tfoot><noframes id='50E87A28D9'>

    • <optgroup id='50E87A28D9'><strike id='50E87A28D9'><sup id='50E87A28D9'></sup></strike><code id='50E87A28D9'></code></optgroup>
        1. <b id='50E87A28D9'><label id='50E87A28D9'><select id='50E87A28D9'><dt id='50E87A28D9'><span id='50E87A28D9'></span></dt></select></label></b><u id='50E87A28D9'></u>
          <i id='50E87A28D9'><strike id='50E87A28D9'><tt id='50E87A28D9'><pre id='50E87A28D9'></pre></tt></strike></i>

          Home / knowledge / focus

          focus


          focus

          author:focus    Page View:97
          Influenza A virions
          F. A. Murphy/CDC

          Vir Biotechnology said Thursday that a long-acting antibody drug designed to protect healthy individuals from influenza A failed to do so in a nearly 3,000-person clinical trial.

          Volunteers who received the highest dose of the drug, known as VIR-2482, were only 16% less likely than the placebo group to develop symptomatic influenza A infections, as defined by trial criteria, over a seven-month period. The difference was not statistically significant.

          advertisement

          The results are a setback in broader efforts to develop better protective measures against both seasonal and potential pandemic influenza strains. In the short term, Vir and outside experts hoped VIR-2482 could provide additional annual protection for at-risk groups like older adults, as flu vaccines are often only modestly effective.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In